
    
      This is a randomized-control clinical trial. After completion the baseline assessment,
      subjects will be randomly assigned to either standard pharmacotherapy or SP+CBSST and will be
      followed for 18 months. The subjects will be 180 outpatients over the age of 45 with a
      diagnosis of schizophrenia or schizoaffective disorder.
    
  